CureVac’s Final Act: Shareholders Seal BioNTech Takeover Deal

The curtain is closing on CureVac’s independent presence in the stock market. Following a conclusive shareholder decision this week, the company’s shares are transitioning from a speculative biotech investment into a straightforward calculation tied to its acquisition by BioNTech. With the market already pricing the transaction as complete, investors face a rapidly closing window to exchange their holdings.

The prolonged uncertainty surrounding the Tübingen-based firm’s future has reached its conclusion. During an extraordinary general meeting, investors created definitive momentum by approving the takeover and its associated restructuring with an overwhelming 99.16 percent majority. This vote removes the final significant obstacle for BioNTech to fully integrate CureVac’s Read more...